GDP方案治疗复发难治性非霍奇金淋巴瘤的临床观察

Clinical efficacy and toxicity of combined chemotherapy with gemcitabine,predisone and cisplatin in patients with recurrent and refractory non-Hodgkin lymphoma

目的:探讨吉西他滨、顺铂、泼尼松组成的GDP方案治疗复发难治性非霍奇金淋巴瘤的疗效和毒副反应。方法:GDP方案:吉西他滨1000mg/m2,加入生理盐水100mL中,静脉滴入(≥30min),d1、d8;DDP25mg/m2,静脉滴入,适当水化,d1～d3;PDN50mg/d,口服,d1～d10,21d为1个周期。全组32例患者接受1～6个周期化疗,平均2.7个周期。结果:27例患者完全缓解6例(22.22%),部分缓解11例(40.74%),总有效率62.96%。毒副反应主要为骨髓抑制,尤其血小板下降,Ⅲ～Ⅳ度血小板下降占全组29.63%。无治疗相关死亡。结论:GDP方案是治疗复发难治性非霍奇金淋巴瘤的一个有效方案,毒副反应可以耐受。

OBJECTIVE： To study the effects and toxicity of gemcitabine combined with cisplatine and prednisone （GDP regimen） in the treatment of non-Hodgkin＇s lymphoma （NHL）. METHODS：Thirty-two patients with NHL were treated with gemcitabine, 1 000 mg/m^2, adding NS 100 mL, ivdrip （≥30 rain）, d1- d8 ; cisplatine, 25 mg/m^2 , being hydrated, ivdrip, di -d3 ; and prednisone, 50 mg/d, po, d1 --d10 ; Twenty-one days as one cycle. All patients received 1--6 cycles of the chemotherapy, and the average number of chemotherapy cycles was 2. 7. RESLUTS： There were 6 cases of CR （22.22%）, 11 cases of PR （40.74%） and the total response rate was 62.96%. The most common toxieities were hematologic,especially thrombocytopenia. Grade Ⅲ or Ⅳ thrombocytopenia occurred in 29.63 % of the patients. No treatment-related deaths occurred. CONCLUSION： GDP Regimen is an active regimen in recurrent or refractory non-Hodgkin lymphoma and can be administered with acceptable toxicity.